// App-Quantinova.ai

POS0097 (2022) : IDENTIFICATION OF NEW CANDIDATE DRUGS FOR PRIMARY SJÖGREN’S SYNDROME USING A DRUG REPURPOSING TRANSCRIPTOMIC APPROACH

Researchers

Presenter

  • R. Felten

Principal Investigators

  • T. Ye

  • C. Schleiss

  • B. Schwikowski

  • J. Sibilia

  • F. Monneaux

  • H. Dumortier

  • R. Jonsson

  • C. Lessard

  • W. F. Ng

  • T. Takeuchi

  • X. Mariette

  • J. E. Gottenberg

Medical Centers

  • Hôpitaux Universitaires de Strasbourg, Service de Rhumatologie, Centre National de Référence des Maladies Auto-immunes Systémiques Rares Est Sud-Ouest (RESO), Strasbourg, France

  • Laboratoire d’Immunologie, Immunopathologie et Chimie Thérapeutique, Institut de Biologie Moléculaire et Cellulaire (IBMC), CNRS UPR3572, Strasbourg, France

  • Pasteur Institute, Systems Biology Group, Department of Computational Biology, Paris, France

  • University of Bergen, Broegelmann Research Laboratory, Department of Clinical Science, N- Bergen, Norway

  • Oklahoma Medical Research Foundation, Department of Pathology, Oklahoma, United States of America

  • Newcastle University, Translational & Clinical Research, Newcastle upon Tyne, United Kingdom

  • Jichi Medical University, Division of Rheumatology and Clinical Immunology, Tochigi, Japan

  • Hôpital Bicètre, APHP, Université Paris-Saclay, Service de Rhumatologie, Paris, France

Locations

  • France

  • Norway

  • United States

  • United Kingdom

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Sjogren's syndrome

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved